



ACC

Strong margins; cut to HOLD on full valuations

- Q3 revenue growth of 8% YoY bolstered by 16% uptick in volumes while realisations moderated 5%
- Cost-saving initiatives saw EBITDA margin climb 10ppt YoY and 600bps QoQ to 18.4%
- We raise FY24/FY25 EPS by 3%/7% and roll over to new TP of Rs 2,542 (vs. Rs 2,158); cut from BUY to HOLD on high valuations

Robust volume growth but realisations moderate: ACC reported an 8% YoY (+11% QoQ) increase in Q3FY24 revenue to Rs 49.2bn backed by sharp volume growth of 16% YoY (+10% QoQ) to 8.9mn tonnes. This includes 1.7mt of sales to ACEM under the master supply agreement or MSA. Q3 realisations fell 5% YoY (+2% QoQ) to Rs 5,225/t. Revenue from ACC's ready-mix concrete (RMC) segment dropped 20% YoY (-3% QoQ) to Rs 3bn, with segmental loss at Rs 45mn.

Cost savings continue: Operating cost softened 16% YoY (-6% QoQ) to Rs 4,511/t owing to lower energy and logistics costs. Energy costs (adjusted for inventory) fell by 16% YoY (-2% QoQ) to Rs 2,647/t due to lower pet coke prices and management's cost reduction initiatives, while logistics costs declined 17% YoY (-8% QoQ) to Rs 1,082/t aided by supply agreements with ACEM. Consequently, EBITDA/t jumped to Rs 1,015 from lows of Rs 491 in Q3FY23 and Rs 677 in Q2FY24, and operating margin expanded to 18.4% off a low base.

Capacity expansion on track: Clinker expansion at Ametha (Uttar Pradesh) became operational during Q3FY24, adding 3.3mt of capacity which will be fully utilised by ACC's split grinding units in the state. Further, grinding unit expansion of 1.6mt at Sindri (Jharkhand) and 2.4mt at Salai Banwa (Uttar Pradesh) is expected to become operational by Q4FY25 and Q1FY26 respectively.

Upsides capped - downgrade to HOLD: Factoring in ACC's healthy 9MFY24 performance contributed by MSA-led synergies and a focus on cost savings, we raise our FY24/FY25 EPS forecasts by 3%/7%. We introduce FY26 estimates and roll valuations over for a revised TP of Rs 2,542 (from Rs 2,158). Our valuation multiple remains at 10x on FY26E EV/EBITDA and implies a replacement cost of Rs 9.2bn/mt - a 30% premium to the industry average given ACC's pan-India presence, size (38mt) and operating efficiencies. However, the stock has run up in the last few months and offers limited upside - we thus downgrade to HOLD from BUY.

02 February 2024

Milind Raginwar | Shree Kirloskar research@bobcaps.in

Key changes

Cement

	Target	Rating	
		•	
Ticker/Pri			
		ACC IN/Rs 2,530	
Market ca		US\$ 5.8bn	
Free float		43%	
3M ADV		US\$ 16.2mn	
52wk high	n/low	Rs 2,584/Rs 1,592	
Promoter	/FPI/DII	57%/12%/19%	

Source: NSE | Price as of 1 Feb 2024

Key financials

Y/E 31 Mar	FY23A	FY24E	FY25E
Total revenue (Rs mn)	2,17,883	1,89,849	2,07,853
EBITDA (Rs mn)	19,400	31,081	35,673
Adj. net profit (Rs mn)	10,926	19,057	22,061
Adj. EPS (Rs)	46.5	101.4	117.4
Consensus EPS (Rs)	46.5	100.0	118.0
Adj. ROAE (%)	7.9	12.8	14.1
Adj. P/E (x)	54.4	25.0	21.6
EV/EBITDA (x)	24.4	14.6	12.0
Adj. EPS growth (%)	(54.3)	118.0	15.8

Source: Company, Bloomberg, BOBCAPS Research | FY23 is for 15 months due to a change in year-end from December to March

Stock performance



Source: NSE





Fig 1 – Key quarterly metrics

Particulars	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ (%)
Volumes (mn mt)	8.9	7.7	15.6	8.10	9.9
Cement realisations (Rs/mt)	5,225	5,497	(5.0)	5,125	1.9
Operating costs (Rs/mt)	4,511	5,401	(16.5)	4,798	(6.0)
EBITDA/t (Rs/mt)	1,015	491	106.6	677	49.9

Source: Company, BOBCAPS Research

Fig 2 – Quarterly performance

(Rs mn)	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ (%)
Net Sales	49,183	45,370	8.4	44,347	10.9
Expenditure					
Change in stock	(768)	1,186	(164.8)	643	(219.4)
Raw material	7,645	6,087	25.6	7,192	6.3
Purchased products	6,547	5,608	16.7	5,110	28.1
Power & fuel	10,136	11,292	(10.2)	8,857	14.4
Freight	9,629	10,073	(4.4)	9,533	1.0
Employee costs	1,783	2,048	(12.9)	1,948	(8.5)
Other expenditure	5,180	5,293	(2.1)	5,581	(7.2)
Total Operating Expenses	40,152	41,587	(3.5)	38,863	3.3
EBITDA	9,032	3,783	138.7	5,484	64.7
EBITDA margin (%)	18.4	8.3	1,002bps	12.4	600bps
Other Income	839	407	106.2	2,079	(59.6)
Interest	339	188	79.9	288	17.5
Depreciation	2,343	1,716	36.6	2,118	10.6
PBT	7,189	2,286	214.5	5,156	39.4
Non-recurring items	0	(791)	0.0	0	0.0
PBT (after non-recurring items)	7,189	1,495	380.9	5,156	39.4
Tax	1,914	390	390.3	1,313	45.8
Reported PAT	5,275	1,104	377.6	3,843	37.3
Adjusted PAT	5,275	1,895	178.3	3,843	37.3
NPM (%)	10.7	4.2	655bps	8.7	206bps
Adjusted EPS (Rs)	28.1	10.1	178.3	20.4	37.3

Source: Company, BOBCAPS Research






Fig 3 – MSA boosts volumes







Fig 5 – EBITDA/t surges off a low base

Source: Company, BOBCAPS Research

Fig 7 – Logistic cost savings may limit levers ahead



Source: Company, BOBCAPS Research

Fig 4 – Weak demand keeps realisations weak






Fig 6 – Cost savings commendable, sustainability is key



Source: Company, BOBCAPS Research

Fig 8 – Fuel cost savings healthy





Valuation methodology

Factoring in ACC's healthy 9MFY24 performance contributed by MSA-led synergies and a focus on cost savings, we raise our FY24/FY25 EPS by 8%/7%. We now introduce FY26 estimates for the company and model for a three-year revenue/ EBITDA/PAT CAGR of 6%/26%30% driven by cost efficiencies. This coupled with rollover of valuations to FY26E results in a higher TP of Rs 2,542 (from Rs 2,158), set at an unchanged 10x EV/EBITDA multiple.

Our TP implies a replacement cost of Rs 9.2bn/mt – a 30% premium to the industry average given ACC's pan-India presence, large size (38mt) and operating efficiencies. However, the stock has run up in the last few months and offers limited upside potential – we thus downgrade to HOLD from BUY.

Fig 9 - Revised estimates

(Rs mn)		New			Old			Change (%)	
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	1,89,849	2,07,853	2,24,865	196,593	218,812	NA	(3.4)	(5.0)	NA
EBITDA	31,081	35,673	38,939	27,692	34,422	NA	12.2	7.7	NA
Adj PAT	19,057	22,061	24,398	16,871	21,146	NA	13.0	9.3	NA
Adj EPS (Rs)	101.4	117.4	129.8	93.8	110	NA	8.1	6.7	NA

Source: BOBCAPS Research

Fig 10 – Key assumptions

Parameter	FY23	FY24E	FY25E	FY26E
Volumes (mt)	38.5	32.6	35.9	35.9
Realisations (Rs/mt)	5169	5143	5221	5325
Operating costs (Rs/mt)	6,802	4,938	4,953	5,047
EBITDA/mt (Rs)	467.9	996.6	989.4	1034.0

Source: Company, BOBCAPS Research

Fig 11 – Valuation summary

Business (Rs mn)	FY25E
Target EV/EBITDA (x)	10
EBITDA	38,939
Target EV	4,06,523
Total EV	4,06,523
Net debt	(71,288)
Target market capitalisation	4,77,811
Target price (Rs/sh)	2,542
Weighted average shares (mn)	188
Source: BOBCADS Desearch	

Source: BOBCAPS Research

Fig 12 – Peer comparison

Ticker Rating		ТР	E١	//EBITDA (x)	E\	//tonne (US	\$)		ROE (%)			ROCE (%)	
Ticker Rating	(Rs)	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	
ACC IN	HOLD	2,542	24.4	14.6	11.5	161	142	134	7.9	12.8	14.7	7.9	17.5	19.2
ACEM IN	HOLD	449	18.0	10.8	8.9	286	215	204	9.3	9.5	10.1	9.2	13.8	14.6
UTCEM IN	HOLD	9,396	24.9	18.0	13.7	229	227	193	9.6	12.5	15.5	12.0	16.4	20.0
SRCM IN	HOLD	24,656	27.4	19.9	15.5	208	207	202	6.7	10.7	13.5	8.6	14.3	17.9

Source: BOBCAPS Research







Fig 13 – EV/EBITDA band: We value ACC at 10x on FY26E

Fig 14 – EV/EBITDA 1Y fwd: Limited upside potential



Source: Company, Bloomberg, BOBCAPS Research









Fig 16 - EV/tonne: Expect reversion to mean



Source: Company, Bloomberg, BOBCAPS Research

Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key upside/downside risks to our estimates are:

- Faster than expected capacity addition helping volume growth
- Further higher than expected cost easing
- Competitive intensity getting fierce putting pricing pressure

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	5.8	2,530	2,542	HOLD
Dalmia Bharat	DALBHARA IN	5.1	2,280	2,443	HOLD
JK Cement	JKCE IN	4.1	4,407	4,121	HOLD
JK Lakshmi Cement	JKLC IN	1.3	930	551	SELL
Orient Cement	ORCMNT IN	0.7	287	128	SELL
The Ramco Cements	TRCL IN	2.8	987	661	SELL
Ultratech Cement	UTCEM IN	34.9	9,922	11,510	BUY

Source: BOBCAPS Research, NSE | Price as of 1 Feb 2024



1.7

9.9

2.5

1.5

8.2

9.2

Financials

Income Statement Y/E 31 Mar (Rs mn) CY21A FY23A FY24E FY25E FY26E 2,24,865 Total revenue 1,58,144 2,17,883 1,89,849 2,07,853 EBITDA 30,004 19,400 31,081 35,673 38,939 Depreciation (5,973) (8,351) (8,909) (9,697) (10,253) EBIT 14,421 26,681 30,935 34,141 26,078 Net interest inc./(exp.) (546) (772) (1,100) (1,323) (1,393) 4,959 Other inc./(exp.) 2.048 3,372 4,509 5,455 Exceptional items (548) (1,618) 0 0 0 EBT 24,984 12,031 25.581 29.612 32.748 Income taxes (6,401) (2,723) (6,523) (7,551) (8,351) Extraordinary items 0 0 0 0 0 Min. int./Inc. from assoc. 0 0 0 0 0 18,583 9,309 19,057 22,061 24,398 Reported net profit Adjustments 548 1,618 0 0 0 Adjusted net profit 19,131 10,926 19,057 22,061 24,398 **Balance Sheet** Y/E 31 Mar (Rs mn) CY21A FY23A FY24E FY25E FY26E

.,	• • • • • • •				
Accounts payables	40,320	43,868	44,229	48,881	53,833
Other current liabilities	20,458	13,592	22,201	23,601	25,141
Provisions	2,300	1,863	1,321	1,331	1,341
Debt funds	0	0	0	0	0
Other liabilities	3,827	4,331	4,384	4,441	4,508
Equity capital	1,880	1,880	1,880	1,880	1,880
Reserves & surplus	1,40,550	1,38,696	1,53,305	1,70,695	1,89,972
Shareholders' fund	1,42,285	1,40,430	1,55,185	1,72,575	1,91,852
Total liab. and equities	2,09,191	2,04,086	2,27,321	2,50,829	2,76,675
Cash and cash eq.	74,042	2,868	21,790	47,762	69,361
Accounts receivables	4,892	8,747	9,007	9,292	9,436
Inventories	12,733	16,235	18,203	19,787	21,252
Other current assets	35,961	82,615	76,212	74,918	75,259
Investments	1,927	1,927	1,927	1,927	1,927
Net fixed assets	66,492	73,113	81,492	81,854	81,050
CWIP	12,408	16,831	18,500	15,000	18,000
Intangible assets	736	1,750	190	290	390
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	2,09,190	2,04,085	2,27,321	2,50,829	2,76,675

Cash Flows

CY21A	FY23A	FY24E	FY25E	FY26E
31,108	(39,898)	37,565	35,453	37,280
(13,342)	(20,113)	(15,879)	(4,810)	(10,560)
2,349	2,652	(15,000)	(25,000)	(25,000)
0	0	0	0	0
(10,994)	(17,461)	(30,879)	(29,810)	(35,560)
0	0	0	0	0
0	0	0	0	0
0	0	0	0	0
(2,629)	(10,892)	(2,856)	(4,614)	(5,054)
(5)	(271)	92	(57)	(67)
(2,634)	(11,163)	(2,764)	(4,671)	(5,121)
17,480	(68,522)	3,922	972	(3,401)
74,042	2,868	21,789	47,762	69,361
	31,108 (13,342) 2,349 0 (10,994) 0 0 0 (2,629) (5) (2,634) 17,480	31,108 (39,898) (13,342) (20,113) 2,349 2,652 0 0 (10,994) (17,461) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (5) (271) (2,634) (11,163) 17,480 (68,522)	31,108 (39,898) 37,565 (13,342) (20,113) (15,879) 2,349 2,652 (15,000) 0 0 0 0 0 0 (10,994) (17,461) (30,879) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (2,629) (10,892) (2,856) (5) (271) 92 (2,634) (11,163) (2,764) 17,480 (68,522) 3,922	31,108 (39,898) 37,565 35,453 (13,342) (20,113) (15,879) (4,810) 2,349 2,652 (15,000) (25,000) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 (2629) (10,892) (2,856) (4,614) (5) (271) 92

Per Share Y/E 31 Mar (Rs) CY21A FY23A FY24E FY25E FY26E 39.6 Reported EPS 117.4 129.8 98.9 101.4 Adjusted EPS 101.8 46.5 101.4 117.4 129.8 Dividend per share 14.0 46.4 20.0 21.0 23.0 Book value per share 756.9 747.0 825.5 918.0 1,020.5 Valuations Ratios CY21A FY23A Y/E 31 Mar (x) FY24E FY25E FY26E EV/Sales 2.5 2.2 2.4 2.1 EV/EBITDA 13.4 24.4 14.6 12.0 Adjusted P/E 24.9 54.4 25.0 21.6 19.5 P/BV 3.3 3.4 3.1 2.8 **DuPont Analysis** FY24E FY26E CY21A FY23A Y/E 31 Mar (%) FY25E Tax burden (Net profit/PBT) 74.4 77.4 74.5 74.5 74.5 Interest burden (PBT/EBIT) 97.9 94.6 95.9 95 7 95.9 EBIT margin (EBIT/Revenue) 16.5 6.6 14.1 14.9 15.2 91.4 Asset turnover (Rev./Avg TA) 83.2 113.1 87.0 89.2 Leverage (Avg TA/Avg Equity) 1.5 1.4 1.5 1.5 Adjusted ROAE 7.9 14.8 12.8 14.1 14.1 Ratio Analysis Y/E 31 Mar CY21A FY23A FY24E FY25E FY26E YoY growth (%) Revenue 17.3 10.2 8.9 9.5 EBITDA 20.9 (48.3) 100.3 14.8 Adjusted EPS 31.9 (54.3) 118.0 15.8 10.6 Profitability & Return ratios (%) EBITDA margin 18.6 8.7 16.1 16.9 17.0 EBIT margin 16.1 6.5 13.8 14.6 14.9 0

Adjusted profit margin	12.1	5.0	10.0	10.6	10.8
Adjusted ROAE	14.8	7.9	12.8	14.1	14.1
ROCE	18.9	7.9	17.5	18.4	18.3
Working capital days (days)					
Receivables	11	18	17	16	15
Inventory	29	34	35	35	34
Payables	112	99	100	102	104
Ratios (x)					
Gross asset turnover	1.5	1.8	1.4	1.5	1.5
Current ratio	2.0	1.9	1.8	2.1	2.2
Net interest coverage ratio	47.7	18.7	24.3	23.4	24.5
Adjusted debt/equity	0.0	0.0	0.0	0.0	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets | FY23 is for 15 months due to a change in year-end from December to March





NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ACC (ACC IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.





The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.